(OCS) Oculis Holding - Performance 50.2% in 12m
Compare OCS with Indices, Sectors and Commodities and Bonds. Who performs better in which timeframe?
Performance Rating
70.65%
#6 in Group
Rel. Strength
90.85%
#733 in Universe
Total Return 12m
50.17%
#23 in Group
Total Return 5y
85.77%
#21 in Group
P/E -
(?) Percentile in Group
P/E Forward -
(?) Percentile in Group
PEG -
(?) Percentile in Group
FCF Yield -8.54%
(?) Percentile in Group
12m Total Return: OCS (50.2%) vs XBI (-12.1%)

5y Drawdown (Underwater) Chart

Top Performers in Biotechnology
Overall best picks of Peer Group Selected by proven GARP Predictive Metrics, sorted by Growth Rating
Symbol | 1m | 12m | 5y | P/E | P/E Forward | PEG | EPS Stability |
EPS CAGR |
---|---|---|---|---|---|---|---|---|
ABBV NYSE AbbVie |
-19.2% | 9.47% | 151% | 75.1 | 14.6 | 0.38 | -49.6% | -19% |
UTHR NASDAQ United Therapeutics |
-11.7% | 23% | 168% | 11.8 | 10.6 | 1.43 | 83.8% | 78.5% |
HLN NYSE Haleon |
-1.45% | 26.1% | 39.7% | 24.7 | 20.3 | 1.8 | 27.1% | - |
AMGN NASDAQ Amgen |
-10.9% | 9.64% | 39.3% | 38.4 | 14.1 | 0.99 | -18.8% | -20% |
LONN SW Lonza |
-3.29% | 3.72% | 31.6% | 60.7 | 31.7 | 1.15 | 12.6% | -10.3% |
BIM PA Biomerieux |
2.96% | 17.6% | 11.9% | 31.5 | 25.4 | 1.47 | -58.7% | -25.1% |
NBIX NASDAQ Neurocrine Biosciences |
-10.2% | -24.7% | -1.51% | 29.1 | 20.7 | 0.27 | 61.5% | 31.6% |
KMDA NASDAQ Kamada |
-6.62% | 33.3% | -5.06% | 24.3 | 22.8 | 0.91 | 47.7% | 3.93% |
Performance Comparison: OCS vs XBI vs S&P 500
XBI (SPDR S&P Biotech ETF) is the Sector Benchmark for OCS
Total Return (including Dividends) | OCS | XBI | S&P 500 |
---|---|---|---|
1 Month | -4.30% | -14.90% | -7.04% |
3 Months | -18.87% | -14.51% | -10.88% |
12 Months | 50.17% | -12.11% | 5.72% |
5 Years | 85.77% | -20.56% | 100.77% |
Trend Score (consistency of price movement) | OCS | XBI | S&P 500 |
1 Month | -76.0% | -85.2% | -76.1% |
3 Months | -90.9% | -87.6% | -86.4% |
12 Months | 83.4% | -24% | 67.8% |
5 Years | 85.2% | -52.8% | 84.3% |
Relative Strength (compared with Indexes) | Rank in Peer Group | vs. XBI | vs. S&P 500 |
1 Month | #43 | 12.5% | 2.94% |
3 Month | #79 | -5.09% | -8.96% |
12 Month | #22 | 70.9% | 42.0% |
5 Years | #15 | 214% | 37.5% |
FAQs
Does OCS Oculis Holding outperforms the market?
Yes,
over the last 12 months OCS made 50.17%, while its related Sector, the SPDR S&P Biotech (XBI) made -12.11%.
Over the last 3 months OCS made -18.87%, while XBI made -14.51%.
Over the last 3 months OCS made -18.87%, while XBI made -14.51%.
Performance Comparison OCS vs Indeces and Sectors
OCS vs. Indices OCS is Over or Underperforming
Symbol | 1w | 1m | 6m | 12m | |
---|---|---|---|---|---|
US S&P 500 | SPY | 15.2% | 2.74% | 35.4% | 44.5% |
US NASDAQ 100 | QQQ | 15.6% | 3.56% | 35.5% | 46.5% |
US Dow Jones Industrial 30 | DIA | 13.3% | 0.87% | 33.5% | 43.5% |
German DAX 40 | DAX | 2.65% | 3.75% | 16.9% | 30.9% |
Shanghai Shenzhen CSI 300 | CSI 300 | 8.15% | 3.45% | 30.6% | 42.2% |
Hongkong Hang Seng | HSI | 7.48% | 6.85% | 34.0% | 34.0% |
India NIFTY 50 | INDA | 11.1% | -7.72% | 36.0% | 49.5% |
Brasil Bovespa | EWZ | 10.6% | 1.98% | 35.1% | 61.1% |
OCS vs. Sectors OCS is Over or Underperforming
Symbol | 1w | 1m | 6m | 12m | |
---|---|---|---|---|---|
Communication Services | XLC | 15.3% | 3.28% | 27.2% | 36.9% |
Consumer Discretionary | XLY | 16.7% | 1.92% | 33.2% | 42.8% |
Consumer Staples | XLP | 9.89% | -4.19% | 27.8% | 37.7% |
Energy | XLE | 14.2% | 7.62% | 36.5% | 63.0% |
Financial | XLF | 12.4% | 0.57% | 27.5% | 30.8% |
Health Care | XLV | 12.7% | 2.48% | 36.6% | 50.3% |
Industrial | XLI | 12.7% | 1.67% | 36.1% | 46.3% |
Materials | XLB | 11.7% | 3.14% | 42.9% | 58.1% |
Real Estate | XLRE | 9.40% | 0.69% | 35.7% | 35.8% |
Technology | XLK | 15.8% | 5.53% | 41.5% | 53.4% |
Utilities | XLU | 9.63% | -2.19% | 31.2% | 23.8% |
Aerospace & Defense | XAR | 10.5% | -3.69% | 26.0% | 27.0% |
Biotech | XBI | 10.6% | 10.6% | 51.3% | 62.3% |
Homebuilder | XHB | 15.8% | 4.91% | 54.9% | 61.9% |
Retail | XRT | 15.4% | 1.45% | 42.7% | 57.2% |